Acrivon Therapeutics Stock Forecast
NASDAQ: ACRVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 3:59 PM ET · Delayed 15 min
ACRV analyst consensus
Consensus (7 analysts)
none
Avg. price target
$11.50+502.09%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Acrivon Therapeutics (2026-10-09), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $11.50, with a high estimate of $19.00 and a low estimate of $7.00. The average target implies upside of 502.1% from the current price of $1.91.
The spread between the highest and lowest targets is 171.4%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ACRV.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 43% |
| Buy | 4 | 57% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +266.49% |
| Average target | $11.50 | +502.09% |
| High target | $19.00 | +894.76% |